Systemic Treatment for Hepatocellular Carcinoma Recurrence After Liver Transplantation

Area of Science:

• Hepatology and Oncology
• Transplantation Medicine
• Cancer Therapeutics

Background:

• Hepatocellular carcinoma (HCC) is a major global cause of cancer mortality.
• Liver transplantation (LT) is the only curative option for HCC, addressing both cancer and liver disease.
• HCC recurrence post-LT affects 8-20% of patients, leading to poor prognoses, especially with early relapse.

Purpose of the Study:

• To review current systemic therapies for recurrent HCC after LT.
• To focus on tyrosine kinase inhibitors (TKIs), immunotherapy, and immunosuppression strategies.
• To highlight the lack of prospective data and reliance on retrospective evidence.

Main Methods:

• Systematic review of existing literature on systemic therapies for post-LT HCC recurrence.
• Analysis of data concerning TKIs, immunotherapies, and immunosuppression protocols.
• Evaluation of evidence quality, noting limitations due to retrospective study designs.

Main Results:

• Management of recurrent HCC post-LT is complicated by required lifelong immunosuppression.
• Immunosuppression may drive tumor progression and limit treatment choices.
• Current treatment decisions rely heavily on retrospective data and expert consensus due to limited prospective studies.

Conclusions:

• There is a critical need for prospective studies evaluating systemic regimens for recurrent HCC post-LT.
• Integrating immunosuppression modulation with systemic therapies is crucial.
• Further research should explore immunotherapy and novel targeted therapies in this patient population.